Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches
Biochemical Pharmacology · 2023
DOI: 10.1016/j.bcp.2023.115705 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Natasa Tosic und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Genetics and Genetic Engineering, Laboratory for Molecular Biomedicine, University of Belgrade, Serbia. Electronic address: na…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 204 Literaturangaben. Gefördert von: Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is a very heterogeneous hematological malignancy that accounts for approximately 20% of all pediatric leukemia cases. The outcome of pediatric AML has improved over the last decades, with overall survival rates reaching up to 70%. Still, AML is among the leading types of pediatric cancers by its high mortality rate. Modulation of standard therapy, like chemotherapy intensification, hematopoietic stem cell transplantation and optimized supportive care, could only get this far, but for the significant improvement of the outcome in pediatric AML, development of novel targeted therapy approaches is necessary. In recent years the advances in genomic techniques have greatly expanded our knowledge of the AML biology, revealing molecular landscape and complexity of the disease, which in turn have led to the identification of novel therapeutic targets. This review provides a brief overview of the genetic landscape of pediatric AML, and how it's used for precise molecular characterization and risk stratification of the patients, and also for the development of effective targeted therapy. Furthermore, this review presents recent advances in molecular targeted therapy and immunotherapy with an emphasis on the therapeutic approaches with significant clinical benefits for pediatric AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Molecular Genetics and Genetic Engineering, Laboratory for Molecular Biomedicine, University of Belgrade, Serbia. Electronic address: natasa.tosic@imgge.bg.ac.rs.
- Institute of Molecular Genetics and Genetic Engineering, Laboratory for Molecular Biomedicine, University of Belgrade, Serbia.
- University Children's Hospital, Department for Hematology and Oncology, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Serbia.
Förderung
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
Zitieren
APA
Tosic, N., Marjanovic, I., & Lazic, J. (2023). Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115705
Vancouver
Tosic N, Marjanovic I, Lazic J. Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115705
BibTeX
@article{Tosic2023,
author = {Tosic, Natasa and Marjanovic, Irena and Lazic, Jelena},
title = {Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches},
journal = {Biochemical Pharmacology},
year = {2023},
doi = {10.1016/j.bcp.2023.115705}
}
EUVIMED